Literature DB >> 23520147

Reliability and minimal detectable change of physical performance measures in individuals with pre-manifest and manifest Huntington disease.

Lori Quinn1, Hanan Khalil, Helen Dawes, Nora E Fritz, Deb Kegelmeyer, Anne D Kloos, Jonathan W Gillard, Monica Busse.   

Abstract

BACKGROUND: Clinical intervention trials in people with Huntington disease (HD) have been limited by a lack of reliable and appropriate outcome measures.
OBJECTIVE: The purpose of this study was to determine the reliability and minimal detectable change (MDC) of various outcome measures that are potentially suitable for evaluating physical functioning in individuals with HD.
DESIGN: This was a multicenter, prospective, observational study.
METHODS: Participants with pre-manifest and manifest HD (early, middle, and late stages) were recruited from 8 international sites to complete a battery of physical performance and functional measures at 2 assessments, separated by 1 week. Test-retest reliability (using intraclass correlation coefficients) and MDC values were calculated for all measures.
RESULTS: Seventy-five individuals with HD (mean age=52.12 years, SD=11.82) participated in the study. Test-retest reliability was very high (>.90) for participants with manifest HD for the Six-Minute Walk Test (6MWT), 10-Meter Walk Test, Timed "Up & Go" Test (TUG), Berg Balance Scale (BBS), Physical Performance Test (PPT), Barthel Index, Rivermead Mobility Index, and Tinetti Mobility Test (TMT). Many MDC values suggested a relatively high degree of inherent variability, particularly in the middle stage of HD. Minimum detectable change values for participants with manifest HD that were relatively low across disease stages were found for the BBS (5), PPT (5), and TUG (2.98). For individuals with pre-manifest HD (n=11), the 6MWT and Four Square Step Test had high reliability and low MDC values. LIMITATIONS: The sample size for the pre-manifest HD group was small.
CONCLUSIONS: The BBS, PPT, and TUG appear most appropriate for clinical trials aimed at improving physical functioning in people with manifest HD. Further research in people with pre-manifest HD is necessary.

Entities:  

Mesh:

Year:  2013        PMID: 23520147     DOI: 10.2522/ptj.20130032

Source DB:  PubMed          Journal:  Phys Ther        ISSN: 0031-9023


  15 in total

1.  Clinimetric properties of the Tinetti Mobility Test, Four Square Step Test, Activities-specific Balance Confidence Scale, and spatiotemporal gait measures in individuals with Huntington's disease.

Authors:  Anne D Kloos; Nora E Fritz; Sandra K Kostyk; Gregory S Young; Deb A Kegelmeyer
Journal:  Gait Posture       Date:  2014-07-28       Impact factor: 2.840

2.  Heart rate variability and falls in Huntington's disease.

Authors:  Daniel E Vigo; Marcelo Merello; Cinthia Terroba-Chambi; Veronica Bruno
Journal:  Clin Auton Res       Date:  2020-02-06       Impact factor: 4.435

3.  Self-Selected Walking Speed is Predictive of Daily Ambulatory Activity in Older Adults.

Authors:  Addie Middleton; George D Fulk; Michael W Beets; Troy M Herter; Stacy L Fritz
Journal:  J Aging Phys Act       Date:  2015-09-15       Impact factor: 1.961

Review 4.  Walking speed: the functional vital sign.

Authors:  Addie Middleton; Stacy L Fritz; Michelle Lusardi
Journal:  J Aging Phys Act       Date:  2014-05-02       Impact factor: 1.961

5.  A Core Set of Outcome Measures for Adults With Neurologic Conditions Undergoing Rehabilitation: A CLINICAL PRACTICE GUIDELINE.

Authors:  Jennifer L Moore; Kirsten Potter; Kathleen Blankshain; Sandra L Kaplan; Linda C OʼDwyer; Jane E Sullivan
Journal:  J Neurol Phys Ther       Date:  2018-07       Impact factor: 3.649

Review 6.  Understanding the Outcomes Measures used in Huntington Disease Pharmacological Trials: A Systematic Review.

Authors:  Noelle E Carlozzi; Angela Miciura; Nicholas Migliore; Praveen Dayalu
Journal:  J Huntingtons Dis       Date:  2014

7.  Effects of a One Year Intensive Multidisciplinary Rehabilitation Program for Patients with Huntington's Disease: a Prospective Intervention Study.

Authors:  Anu Piira; Marleen R van Walsem; Geir Mikalsen; Kjell Haavik Nilsen; Synnove Knutsen; Jan C Frich
Journal:  PLoS Curr       Date:  2013-09-20

8.  Cognitive Dysfunction Contributes to Mobility Impairments in Huntington's Disease.

Authors:  Anne D Kloos; Deb A Kegelmeyer; Nora E Fritz; Allison M Daley; Gregory S Young; Sandra K Kostyk
Journal:  J Huntingtons Dis       Date:  2017

9.  Rating Scales and Performance-based Measures for Assessment of Functional Ability in Huntington's Disease: Critique and Recommendations.

Authors:  Tiago A Mestre; Monica Busse; Aileen M Davis; Lori Quinn; Filipe B Rodrigues; Jean-Marc Burgunder; Noelle E Carlozzi; Francis Walker; Aileen K Ho; Cristina Sampaio; Christopher G Goetz; Esther Cubo; Pablo Martinez-Martin; Glenn T Stebbins
Journal:  Mov Disord Clin Pract       Date:  2018-05-09

10.  Supporting physical activity engagement in people with Huntington's disease (ENGAGE-HD): study protocol for a randomized controlled feasibility trial.

Authors:  Monica Busse; Lori Quinn; Helen Dawes; Carys Jones; Mark Kelson; Vincent Poile; Rob Trubey; Julia Townson; Rhiannon Tudor Edwards; Anne Rosser; Kerenza Hood
Journal:  Trials       Date:  2014-12-12       Impact factor: 2.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.